Bill Anderson, Roche Pharmaceuticals CEO (Photographer: David Paul Morris, via Getty Images)

August 16, 2022 10:23 AM EDTUpdated 02:06 PM

Roche’s Polivy continues its regulatory dance, will head to FDA for a form of blood cancer

Tyler Patchen

News Reporter

While Roche has previously touted Polivy data for diffuse large B-cell lymphoma (DLBCL), the drug has faced some delays on the regulatory side. But the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche’s Polivy continues its regulatory dance, will head to FDA for a form of blood cancer

Tyler Patchen

News Reporter

Sign up to read this article for free.

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Roche’s Po­livy con­tin­ues its reg­u­la­to­ry dance, will head to FDA for a form of blood can­cer

Tyler Patchen

News Reporter

Sign up to read this article for free.

more like this

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Roche’s Polivy continues its regulatory dance, will head to FDA for a form of blood cancer

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings